BioLineRx holds annual shareholder meeting
BLRX•BioLineRx held its annual shareholder meeting on Sept. 23, 2026. Shareholders reappointed three Class III directors through 2029, approved an increase in authorized share capital and director equity awards, and reappointed Kesselman & Kesselman as auditor for 2026.
1. Meeting approvals
Shareholders endorsed the reappointment of Dr. Aharon Schwartz, Dr. Sandra Panem and Dr. Shaoyu Yan as Class III directors through 2029. They adopted an increase in authorized share capital, including an amendment to the articles of association, and authorized equity-based awards for certain directors; implementation details, award terms and timing were not specified. Kesselman & Kesselman, a PwC member firm, was reappointed as independent auditor for the year ending Dec. 31, 2026.
